Drug intelligence / Profile preview

INH-243

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules

Overview

INH-243 is a nucleotide polymerase inhibitor initially developed by Inhibitex for the treatment of Hepatitis C virus (HCV). It was in Phase II clinical development when Bristol-Myers Squibb acquired Inhibitex, aiming to bolster its direct-acting antiviral pipeline and address potential profit erosion from patent expiries.

Targets

NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on INH-243.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INH-243.

Explore the full profile